Compare Atlassian Corporation PLC (TEAM) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atlassian Corporation PLC vs Travere Therapeutics Inc. Common Stock — how do they compare? Atlassian Corporation PLC trades at $204.54 (market cap $52.66B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Atlassian Corporation PLC is far larger — about 10.8× Travere Therapeutics Inc. Common Stock's market cap, and Atlassian Corporation PLC is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Atlassian Corporation PLC for 65 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| TEAM | TVTX | |
|---|---|---|
Market Cap | $52.66B | $4.88B |
Volume | 2,601,329 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $208.04 | $67.52 |
52-Week Low | $57.15 | $26.79 |
Typical Hold Time | 65 Days | 0 Days |
Enterprise Value | $52.66B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Atlassian (TEAM) trades at $204.66, down 1.49% on the day, with a bullish technical signal from moving averages but overbought short-term RSI. The company shows strong revenue growth, improving net losses, and consistent earnings beats, though profitability metrics remain negative. Recent news highlights AI-driven growth catalysts and cloud momentum.
The outlook is positive given analyst consensus and AI adoption, but high valuation ratios and persistent net losses pose risks. Upside is supported by a large addressable market and subscription growth, while competition and execution challenges are key concerns for investors.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
